AstraZeneca (AZN) Stock Overview
A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 6/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
AZN Community Fair Values
Create NarrativeSee what 154 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
AstraZeneca PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£1,834.50 |
| 52 Week High | UK£1,848.00 |
| 52 Week Low | UK£1,226.00 |
| Beta | 0.19 |
| 1 Month Change | 5.55% |
| 3 Month Change | 8.04% |
| 1 Year Change | 15.85% |
| 3 Year Change | 27.18% |
| 5 Year Change | 118.26% |
| Change since IPO | 379.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| AZN | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 6.1% | -15.0% | -1.0% |
| 1Y | 15.9% | -14.9% | 2.5% |
Return vs Industry: AZN exceeded the Swedish Pharmaceuticals industry which returned -14.9% over the past year.
Return vs Market: AZN exceeded the Swedish Market which returned 2.5% over the past year.
Price Volatility
| AZN volatility | |
|---|---|
| AZN Average Weekly Movement | 3.3% |
| Pharmaceuticals Industry Average Movement | 9.0% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in SE Market | 12.0% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: AZN has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: AZN's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 94,300 | Pascal Claude Soriot | www.astrazeneca.com |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya.
AstraZeneca PLC Fundamentals Summary
| AZN fundamental statistics | |
|---|---|
| Market cap | SEK 2.85t |
| Earnings (TTM) | SEK 91.16b |
| Revenue (TTM) | SEK 523.68b |
Is AZN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AZN income statement (TTM) | |
|---|---|
| Revenue | US$58.74b |
| Cost of Revenue | US$10.77b |
| Gross Profit | US$47.97b |
| Other Expenses | US$37.74b |
| Earnings | US$10.23b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Apr 29, 2026
| Earnings per share (EPS) | 6.59 |
| Gross Margin | 81.66% |
| Net Profit Margin | 17.41% |
| Debt/Equity Ratio | 57.3% |
How did AZN perform over the long term?
See historical performance and comparisonDividends
Does AZN pay a reliable dividends?
See AZN dividend history and benchmarks| AstraZeneca dividend dates | |
|---|---|
| Ex Dividend Date | Feb 19 2026 |
| Dividend Pay Date | Mar 23 2026 |
| Days until Ex dividend | 3 days |
| Days until Dividend pay date | 35 days |
Does AZN pay a reliable dividends?
See AZN dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/15 13:58 |
| End of Day Share Price | 2026/02/13 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AstraZeneca PLC is covered by 57 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| John Eade | Argus Research Company |
| Odile Rundquist | Baader Helvea Equity Research |